DrFirst vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
E-prescribing, medication history, and patient safety platform processing hundreds of millions of Rx transactions annually. Rockville MD; founded 2000; embedded in hundreds of EHR and clinical workflow platforms;
About
DrFirst is a health IT company that has been at the forefront of e-prescribing and medication management since its founding in 2000. Headquartered in Rockville, Maryland, DrFirst provides e-prescribing for controlled substances (EPCS), medication history retrieval, clinical decision support, and patient medication adherence tools to hospitals, physician practices, long-term care facilities, and health IT vendors. The company processes hundreds of millions of prescription transactions annually and is embedded in a wide range of EHR and clinical workflow platforms through its APIs and SDK integrations.\n\nDrFirst's flagship EPCS solution was among the earliest to achieve DEA compliance for electronic prescribing of controlled substances, a capability that has become essential as regulatory requirements and clinical adoption have expanded across all states. The company's medication history service aggregates pharmacy and payer claims data to give providers a more complete view of a patient's actual medication use, supporting medication reconciliation at transitions of care and reducing adverse drug events. DrFirst also offers Backline, a secure clinical communication platform for care team messaging.\n\nDrFirst occupies a specialized but critical position in the health IT ecosystem, providing medication-related infrastructure that EHR vendors embed in their platforms rather than build independently. This embedded model gives DrFirst broad distribution across the provider market and creates sticky, long-term customer relationships. The company has invested in expanding its clinical intelligence capabilities, including AI-driven prior authorization for specialty medications and smart alerts that surface relevant clinical guidance at the point of prescribing.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.